G-BA decisions from 12 May 2023

Here are the G-BA decisions from the G-BA meeting held on 12 May 2023 on the early benefit assessments of Tezpire, Adtralza and Quviviq.

A complete database of all previous G-BA resolutions is available through my membership.

  • Tezpire (tezepelumab); bronchial asthma, patients aged ≥ 12 years – For both subgroups, additional benefit not proven
  • Adtralza (tralokinumab); new indication: atopic dermatitis, patients aged 12 to 17 years – Additional benefit not proven
  • Quviviq (daridorexant); sleep disorders – Additional benefit not proven
  • Hemgenix (etranacogen dezaparvovec); haemophilia B – Request for real-world data collection and restriction of prescribing

Follow me on Instagram to never miss the latest G-BA decisions (here 12 May 2023):

Want my free guide about German HTA?

X